Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
AssigneeMitsubishi Chemical Corporation
InventorsSaiko Hosokawa, Toshiaki Tagawa, Yoko Hirakawa, Norihiko Ito, Kazuhiro Nagaike
Life of this patent
Estimating the term…
Abstract
A human monoclonal antibody specifically binding to a surface antigen of cancer cell membrane, an isolated DNA encoding the antibody, and a hybridoma producing the antibody. An anti-cancer formulation comprising the monoclonal antibody bonded to the surface of a liposome enclosing an anti-cancer agent or toxin is also provided.
Claims20
A pharmaceutical composition comprising a therapeutically effective amount of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells and a pharmaceutically acceptable carrier therefor,
- said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine,
- said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of the liposome through a maleimide group,
- said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane, and
- said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:5 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:6.
A pharmaceutical composition comprising a therapeutically effective amount of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells and a pharmaceutically acceptable carrier therefor,
- said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine,
- said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of the liposome through a maleimide group,
- said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane,
- said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:11 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:12.
A liposome/antibody conjugate consisting essentially of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells,
- said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine,
- said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of a liposome through a maleimide group,
- said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane, and
- said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:5 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:6.
A liposome/antibody conjugate consisting essentially of a monoclonal antibody fragment bound to the surface of a liposome enclosing an anti-cancer agent or toxin to cancer cells,
- said liposome comprising phosphatidylcholine, cholesterol and phosphatidylethanolamine,
- said liposome being modified with poly(ethylene glycol), wherein the poly(ethylene glycol) is bound to the surface of a liposome through a maleimide group,
- said antibody fragment belonging to IgG class or IgM class and specifically binding to a surface antigen of a stomach and colon cancer cell membrane, and
- said antibody fragment having a variable region of the heavy chain which comprises the amino acid sequence shown in SEQ ID No:11 and having a variable region of the light chain which comprises the amino acid sequence shown in SEQ ID No:12.
Dependencies are inferred from the claim text.